Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029
The global cancer biomarkers market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period. Factors like the rapid improvements in technology propel market expansion. in the creation of cancer biomarkers and the global rise in cancer incidence. However, the main obstacles to this market's expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.
“Omics technologies segment accounted for the highest CAGR”
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2023. This is explained by the growing use of proteomics and genomics in medication development and discovery as well as improved cancer diagnostics.
“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period”
The market for cancer biomarkers is divided into categories according on the kind of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. In the market for cancer biomarkers in 2023, the breast cancer category had the fastest growth rate. increasing progress in technology The increasing global prevalence of cancer and the development of cancer biomarkers are two important aspects driving this segment's growth.
“Diagnostics segment accounted for the highest share”
The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. 2020 had the highest CAGR in the research and development sector. This can be linked to the rise in cancer biomarker research and development as well as the growing application of cancer biomarkers in medication discovery and development.
“Diagnostic Laboratories segment accounted for the highest share”
Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. In 2023, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. he expanding number of clinical laboratories performing cancer biomarker-based diagnostics tests worldwide and the rising prevalence of malignancies are responsible for this end-user segment's sizeable share.
“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkers market in this region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This research report categorizes the cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Surface disinfectant market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarker market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“Omics technologies segment accounted for the highest CAGR”
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2023. This is explained by the growing use of proteomics and genomics in medication development and discovery as well as improved cancer diagnostics.
“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period”
The market for cancer biomarkers is divided into categories according on the kind of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. In the market for cancer biomarkers in 2023, the breast cancer category had the fastest growth rate. increasing progress in technology The increasing global prevalence of cancer and the development of cancer biomarkers are two important aspects driving this segment's growth.
“Diagnostics segment accounted for the highest share”
The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. 2020 had the highest CAGR in the research and development sector. This can be linked to the rise in cancer biomarker research and development as well as the growing application of cancer biomarkers in medication discovery and development.
“Diagnostic Laboratories segment accounted for the highest share”
Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. In 2023, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. he expanding number of clinical laboratories performing cancer biomarker-based diagnostics tests worldwide and the rising prevalence of malignancies are responsible for this end-user segment's sizeable share.
“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkers market in this region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level (27%), Director-level (18%), and Others (55%)
- By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Illumina, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Abbott Laboratories (US)
- bioMйrieux SA (US)
- Becton, Dickinson and Company (US)
- Merck Millipore (US)
- Agilent Technologies (US)
- Myriad Genetics, Inc. (US)
- Sysmex Corporation (Japan)
- Hologic, Inc. (US)
- Quest Diagnostics (US)
- Centogene N.V. (Germany)
- BioGenex (India),
- Siemens Healthineers (Germany)
- Exact Sciences (US)
- R&D Systems, Inc. (US)
- BioVision, Inc. (US)
- Olink (Sweden)
- Asuragen, Inc. (US)
- Meso Scale Diagnostics, LLC (US)
- Invivoscribe, Inc. (US)
- INOVIQ Ltd. (Australia)
This research report categorizes the cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Surface disinfectant market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarker market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (High prevalence of cancer, growing use for research and diagnosis), restraints (Technical issues related to sample collection and storage), opportunities (Rising healthcare expenditure, Increasing Demand from Emerging Economies), and challenges (lack of skilled professionals) influencing the growth of the cancer biomarker market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cancer biomarker market
- Market Development: Comprehensive information about lucrative markets – the report analyses the cancer biomarker market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarker market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), among others in cancer biomarker market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 CANCER BIOMARKERS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 CANCER BIOMARKERS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 CANCER BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 CANCER BIOMARKERS MARKET OVERVIEW
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET
4.2 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029
FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029
FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029
4.4 CANCER BIOMARKERS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE CANCER BIOMARKERS MARKET IN 2024
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2024 VS. 2029
FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029
4.6 CANCER BIOMARKERS MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in cancer biomarkers
5.2.1.2 Increasing incidence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015–2035
5.2.1.3 Rising use of cancer biomarkers in drug discovery & development
5.2.1.4 Increasing R&D on cancer biomarkers
5.2.2 RESTRAINTS
5.2.2.1 Technical issues related to sample collection and storage
5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
5.2.2.3 Unfavorable regulatory and reimbursement scenarios
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicine
FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT
FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
5.2.3.2 Growing applications of companion diagnostics
TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
5.2.3.3 Emerging economies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with cancer biomarker validation
5.2.4.2 Shortage of skilled professionals
5.3 PRICING ANALYSIS
5.3.1 PRICING MODEL ANALYSIS
TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023)
TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014–DECEMBER 2023)
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 INTRODUCTION
5.9.2 CANCER BIOMARKERS QUALIFICATION IN US
5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU
FIGURE 30 CANCER BIOMARKERS MARKET: EMA QUALIFICATION PROCEDURE
5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US
5.9.5 EMA APPROVALS
5.9.6 FDA APPROVALS
5.10 TRADE ANALYSIS
5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY TECHNOLOGIES
5.13.1 POLYMERASE CHAIN REACTION
5.13.2 NEXT-GENERATION SEQUENCING
5.14 COMPLEMENTARY TECHNOLOGIES
5.14.1 IN SITU HYBRIDIZATION
5.15 ADJACENT TECHNOLOGIES
5.15.1 IMMUNOHISTOCHEMISTRY
5.16 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 11 CANCER BIOMARKERS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR CANCER BIOMARKERS MARKET
FIGURE 31 REVENUE SHIFT FOR CANCER BIOMARKERS MARKET
5.18 KEY STAKEHOLDERS & BUYING CRITERIA
5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
5.18.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS
5.20 INVESTMENT & FUNDING SCENARIO
TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021–2024
6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
6.1 INTRODUCTION
TABLE 15 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 OMICS TECHNOLOGIES
TABLE 16 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 17 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.2.1 PROTEOMICS
TABLE 18 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 19 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.1.1 Immunoassays
6.2.1.1.1 Facilitate diagnosis of cancer at early stage
TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.2 Mass spectrometry
6.2.1.2.1 High specificity of mass spectroscopy to drive adoption
TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.3 2D gel electrophoresis
6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.4 Protein microarrays
6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.5 Other proteomic technologies
TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2 GENOMICS
TABLE 25 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 26 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.2.1 Next-generation sequencing
6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.2 Polymerase chain reaction
6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
TABLE 28 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.3 In situ hybridization
6.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
TABLE 29 IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 OTHER OMICS TECHNOLOGIES
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3 IMAGING TECHNOLOGIES
TABLE 31 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 32 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3.1 ULTRASOUND IMAGING
6.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
TABLE 33 ULTRASOUND IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 COMPUTED TOMOGRAPHY
6.3.2.1 Technological advancements to drive adoption
TABLE 34 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 MAGNETIC RESONANCE IMAGING
6.3.3.1 Growing preference for open MRIs to support market growth
TABLE 35 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.4 POSITRON EMISSION TOMOGRAPHY
6.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.5 MAMMOGRAPHY
6.3.5.1 Advanced technologies like 3D mammography to support market growth
TABLE 37 MAMMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE
7.1 INTRODUCTION
TABLE 38 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 39 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
7.2 BREAST CANCER
7.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
TABLE 40 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 41 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
7.3 LUNG CANCER
7.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
TABLE 42 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 43 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
7.4 COLORECTAL CANCER
7.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
TABLE 44 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 45 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
7.5 PROSTATE CANCER
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
TABLE 46 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION)
7.6 MELANOMA
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
TABLE 47 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
TABLE 48 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2022–2029 (USD MILLION)
7.7 LEUKEMIA
7.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
TABLE 49 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2022–2029 (USD MILLION)
7.8 THYROID CANCER
7.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
TABLE 50 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2022–2029 (USD MILLION)
7.9 BLADDER CANCER
7.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
TABLE 51 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2022–2029 (USD MILLION)
7.10 NON-HODGKIN’S LYMPHOMA
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
TABLE 52 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2022–2029 (USD MILLION)
7.11 KIDNEY CANCER
7.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
TABLE 53 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
7.12 OTHER CANCERS
TABLE 54 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
8 CANCER BIOMARKERS MARKET, BY PRODUCT
8.1 INTRODUCTION
TABLE 55 CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
8.2 INSTRUMENTS
TABLE 56 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 57 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 Technological advancements in imaging instruments to drive growth
TABLE 58 IMAGING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2 PATHOLOGY-BASED INSTRUMENTS
8.2.2.1 Rising demand for cancer diagnosis to drive market
TABLE 59 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.3 BIOPSY INSTRUMENTS
8.2.3.1 Increasing prevalence of cancer to drive growth
TABLE 60 BIOPSY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 CONSUMABLES
TABLE 61 CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 62 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.1 ANTIBODIES
8.3.1.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
TABLE 63 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.2 KITS & REAGENTS
8.3.2.1 Ease of use to support adoption
TABLE 64 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.3 PROBES
8.3.3.1 Need for probes in assay tests for cancer detection to support market growth
TABLE 65 PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.4 BIOINFORMATICS SOFTWARE
8.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
TABLE 66 CANCER BIOMARKER BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
9 CANCER BIOMARKERS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 67 CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
TABLE 68 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.3 RESEARCH & DEVELOPMENT
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 69 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.4 PROGNOSTICS
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
TABLE 70 CANCER BIOMARKERS MARKET FOR PROGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.5 RISK ASSESSMENT
9.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
TABLE 71 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 72 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 CANCER BIOMARKERS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 73 CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
TABLE 74 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
10.3 BIOPHARMACEUTICAL COMPANIES AND CROS
10.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
TABLE 75 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2022–2029 (USD MILLION)
10.4 RESEARCH AND ACADEMIC INSTITUTES
10.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
TABLE 76 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
10.5 OTHER END USERS
TABLE 77 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
11 CANCER BIOMARKERS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 78 CANCER BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
TABLE 79 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
FIGURE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 80 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 87 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing use of cancer biomarkers for cancer treatment to drive market
TABLE 92 KEY GROWTH STRATEGIES BY LEADING PLAYERS FOR DEVELOPMENT OF CANCER BIOMARKERS
TABLE 93 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 94 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 95 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 100 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 101 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 104 US: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing government initiatives for discovery and development of cancer biomarkers to drive growth
TABLE 105 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 106 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 107 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 112 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 113 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 115 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 116 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 117 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 125 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government health policies to drive market
TABLE 129 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 130 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 135 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 136 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 139 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Availability of government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
TABLE 140 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 141 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 146 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 147 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 150 UK: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increasing government investments in genomics & proteomics research to drive market
TABLE 151 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 152 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 153 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 156 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 157 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 158 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 161 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population to support market growth
TABLE 162 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 163 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 164 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 168 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 169 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 172 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing focus on personalized medicine to propel market
TABLE 173 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 174 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 179 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 180 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 183 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 184 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 185 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 190 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 191 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 194 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 195 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 197 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Advancements in healthcare facilities to drive market
TABLE 207 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 208 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 209 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 214 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 215 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 218 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Research initiatives to support market growth
TABLE 219 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 220 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 221 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 222 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 226 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 227 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increased demand for early cancer diagnosis to drive market
TABLE 231 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 232 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 233 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 238 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 239 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 242 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 243 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 256 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 258 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 259 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 261 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 262 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 265 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Increasing incidence of cancer to drive market
TABLE 266 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 267 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 272 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 273 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 276 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Growing medical tourism to fuel demand for cancer diagnostics
TABLE 277 MEXICO: NUMBER OF CANCER CASES, BY CANCER TYPE, 2022
TABLE 278 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 279 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 284 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 285 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 288 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 289 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 295 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 296 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 299 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
TABLE 300 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 306 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 307 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 310 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11.7 GCC
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
TABLE 311 GCC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 312 GCC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 GCC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 314 GCC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 GCC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 GCC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 317 GCC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 318 GCC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 GCC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 GCC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 GCC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7.2 GCC: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER BIOMARKERS MARKET
TABLE 322 CANCER BIOMARKERS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2019–2023 (USD MILLION)
12.4 MARKET SHARE ANALYSIS
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 323 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT
12.5.5.1 Overall company footprint
FIGURE 39 CANCER BIOMARKERS MARKET: OVERALL COMPANY FOOTPRINT
12.5.5.2 Product footprint
TABLE 324 CANCER BIOMARKERS MARKET: PRODUCT FOOTPRINT
12.5.5.3 Profiling technology footprint
TABLE 325 CANCER BIOMARKERS MARKET: PROFILING TECHNOLOGY FOOTPRINT
12.5.5.4 Application footprint
TABLE 326 CANCER BIOMARKERS MARKET: APPLICATION FOOTPRINT
12.5.5.5 Regional footprint
TABLE 327 CANCER BIOMARKERS MARKET: REGIONAL FOOTPRINT
12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES (2023)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 40 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING
TABLE 328 CANCER BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 329 CANCER BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.7 VALUATION AND FINANCIAL METRICS OF CANCER BIOMARKER VENDORS
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 43 PRODUCT/BRAND COMPARATIVE ANALYSIS
12.8.1 F. HOFFMANN-LA ROCHE LTD.
12.8.2 AGILENT TECHNOLOGIES, INC.
12.8.3 QIAGEN
12.8.4 ABBOTT
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 330 CANCER BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
12.9.2 DEALS
TABLE 331 CANCER BIOMARKERS MARKET: DEALS, JANUARY 2021–MARCH 2024
13 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 332 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 333 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
TABLE 334 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 335 F. HOFFMANN-LA ROCHE LTD.: DEALS
13.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 336 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 337 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
TABLE 338 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 339 THERMO FISHER SCIENTIFIC INC.: DEALS
13.1.3 QIAGEN
TABLE 340 QIAGEN: COMPANY OVERVIEW
FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 341 QIAGEN: PRODUCTS & SERVICES OFFERED
TABLE 342 QIAGEN: PRODUCT LAUNCHES & APPROVALS
TABLE 343 QIAGEN: DEALS
13.1.4 BIO-RAD LABORATORIES, INC.
TABLE 344 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 345 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
13.1.5 ILLUMINA, INC.
TABLE 346 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 48 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 347 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
TABLE 348 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 349 ILLUMINA, INC.: DEALS
13.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS
13.1.7 ABBOTT LABORATORIES
TABLE 354 ABBOTT: COMPANY OVERVIEW
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
TABLE 355 ABBOTT: PRODUCTS & SERVICES OFFERED
13.1.8 BIOMЙRIEUX
TABLE 356 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 51 BIOMЙRIEUX: COMPANY SNAPSHOT (2023)
TABLE 357 BIOMЙRIEUX: PRODUCTS & SERVICES OFFERED
13.1.9 MERCK KGAA
TABLE 358 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 359 MERCK KGAA: PRODUCTS & SERVICES OFFERED
TABLE 360 MERCK KGAA: DEALS
TABLE 361 MERCK KGAA: OTHER DEVELOPMENTS
13.1.10 BECTON, DICKINSON AND COMPANY
TABLE 362 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 363 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MYRIAD GENETICS, INC.
13.2.2 SYSMEX CORPORATION
13.2.3 HOLOGIC, INC.
13.2.4 QUEST DIAGNOSTICS
13.2.5 CENTOGENE N.V.
13.2.6 BIOGENEX
TABLE 364 BIOGENEX: COMPANY OVERVIEW
13.2.7 SIEMENS HEALTHINEERS
13.2.8 EXACT SCIENCES
13.2.9 R&D SYSTEMS, INC.
13.2.10 BIOVISION INC.
13.2.11 OLINK
13.2.12 ASURAGEN, INC.
13.2.13 MESO SCALE DIAGNOSTICS, LLC
13.2.14 INVIVOSCRIBE, INC.
13.2.15 INOVIQ LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 CANCER BIOMARKERS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 CANCER BIOMARKERS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 CANCER BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 CANCER BIOMARKERS MARKET OVERVIEW
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET
4.2 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029
FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029
FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029
4.4 CANCER BIOMARKERS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE CANCER BIOMARKERS MARKET IN 2024
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2024 VS. 2029
FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029
4.6 CANCER BIOMARKERS MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in cancer biomarkers
5.2.1.2 Increasing incidence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015–2035
5.2.1.3 Rising use of cancer biomarkers in drug discovery & development
5.2.1.4 Increasing R&D on cancer biomarkers
5.2.2 RESTRAINTS
5.2.2.1 Technical issues related to sample collection and storage
5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
5.2.2.3 Unfavorable regulatory and reimbursement scenarios
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicine
FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT
FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
5.2.3.2 Growing applications of companion diagnostics
TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
5.2.3.3 Emerging economies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with cancer biomarker validation
5.2.4.2 Shortage of skilled professionals
5.3 PRICING ANALYSIS
5.3.1 PRICING MODEL ANALYSIS
TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023)
TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014–DECEMBER 2023)
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 INTRODUCTION
5.9.2 CANCER BIOMARKERS QUALIFICATION IN US
5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU
FIGURE 30 CANCER BIOMARKERS MARKET: EMA QUALIFICATION PROCEDURE
5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US
5.9.5 EMA APPROVALS
5.9.6 FDA APPROVALS
5.10 TRADE ANALYSIS
5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY TECHNOLOGIES
5.13.1 POLYMERASE CHAIN REACTION
5.13.2 NEXT-GENERATION SEQUENCING
5.14 COMPLEMENTARY TECHNOLOGIES
5.14.1 IN SITU HYBRIDIZATION
5.15 ADJACENT TECHNOLOGIES
5.15.1 IMMUNOHISTOCHEMISTRY
5.16 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 11 CANCER BIOMARKERS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR CANCER BIOMARKERS MARKET
FIGURE 31 REVENUE SHIFT FOR CANCER BIOMARKERS MARKET
5.18 KEY STAKEHOLDERS & BUYING CRITERIA
5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
5.18.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS
5.20 INVESTMENT & FUNDING SCENARIO
TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021–2024
6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
6.1 INTRODUCTION
TABLE 15 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 OMICS TECHNOLOGIES
TABLE 16 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 17 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.2.1 PROTEOMICS
TABLE 18 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 19 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.1.1 Immunoassays
6.2.1.1.1 Facilitate diagnosis of cancer at early stage
TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.2 Mass spectrometry
6.2.1.2.1 High specificity of mass spectroscopy to drive adoption
TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.3 2D gel electrophoresis
6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.4 Protein microarrays
6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.5 Other proteomic technologies
TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2 GENOMICS
TABLE 25 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 26 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.2.1 Next-generation sequencing
6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.2 Polymerase chain reaction
6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
TABLE 28 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.3 In situ hybridization
6.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
TABLE 29 IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 OTHER OMICS TECHNOLOGIES
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3 IMAGING TECHNOLOGIES
TABLE 31 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 32 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3.1 ULTRASOUND IMAGING
6.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
TABLE 33 ULTRASOUND IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 COMPUTED TOMOGRAPHY
6.3.2.1 Technological advancements to drive adoption
TABLE 34 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 MAGNETIC RESONANCE IMAGING
6.3.3.1 Growing preference for open MRIs to support market growth
TABLE 35 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.4 POSITRON EMISSION TOMOGRAPHY
6.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.5 MAMMOGRAPHY
6.3.5.1 Advanced technologies like 3D mammography to support market growth
TABLE 37 MAMMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE
7.1 INTRODUCTION
TABLE 38 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 39 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
7.2 BREAST CANCER
7.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
TABLE 40 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 41 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
7.3 LUNG CANCER
7.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
TABLE 42 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 43 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
7.4 COLORECTAL CANCER
7.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
TABLE 44 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 45 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
7.5 PROSTATE CANCER
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
TABLE 46 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION)
7.6 MELANOMA
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
TABLE 47 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
TABLE 48 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2022–2029 (USD MILLION)
7.7 LEUKEMIA
7.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
TABLE 49 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2022–2029 (USD MILLION)
7.8 THYROID CANCER
7.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
TABLE 50 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2022–2029 (USD MILLION)
7.9 BLADDER CANCER
7.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
TABLE 51 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2022–2029 (USD MILLION)
7.10 NON-HODGKIN’S LYMPHOMA
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
TABLE 52 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2022–2029 (USD MILLION)
7.11 KIDNEY CANCER
7.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
TABLE 53 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
7.12 OTHER CANCERS
TABLE 54 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
8 CANCER BIOMARKERS MARKET, BY PRODUCT
8.1 INTRODUCTION
TABLE 55 CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
8.2 INSTRUMENTS
TABLE 56 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 57 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 Technological advancements in imaging instruments to drive growth
TABLE 58 IMAGING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2 PATHOLOGY-BASED INSTRUMENTS
8.2.2.1 Rising demand for cancer diagnosis to drive market
TABLE 59 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.3 BIOPSY INSTRUMENTS
8.2.3.1 Increasing prevalence of cancer to drive growth
TABLE 60 BIOPSY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 CONSUMABLES
TABLE 61 CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 62 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.1 ANTIBODIES
8.3.1.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
TABLE 63 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.2 KITS & REAGENTS
8.3.2.1 Ease of use to support adoption
TABLE 64 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.3 PROBES
8.3.3.1 Need for probes in assay tests for cancer detection to support market growth
TABLE 65 PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.4 BIOINFORMATICS SOFTWARE
8.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
TABLE 66 CANCER BIOMARKER BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
9 CANCER BIOMARKERS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 67 CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
TABLE 68 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.3 RESEARCH & DEVELOPMENT
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 69 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.4 PROGNOSTICS
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
TABLE 70 CANCER BIOMARKERS MARKET FOR PROGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.5 RISK ASSESSMENT
9.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
TABLE 71 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 72 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 CANCER BIOMARKERS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 73 CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
TABLE 74 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
10.3 BIOPHARMACEUTICAL COMPANIES AND CROS
10.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
TABLE 75 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2022–2029 (USD MILLION)
10.4 RESEARCH AND ACADEMIC INSTITUTES
10.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
TABLE 76 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
10.5 OTHER END USERS
TABLE 77 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
11 CANCER BIOMARKERS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 78 CANCER BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
TABLE 79 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
FIGURE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 80 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 87 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing use of cancer biomarkers for cancer treatment to drive market
TABLE 92 KEY GROWTH STRATEGIES BY LEADING PLAYERS FOR DEVELOPMENT OF CANCER BIOMARKERS
TABLE 93 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 94 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 95 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 100 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 101 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 104 US: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing government initiatives for discovery and development of cancer biomarkers to drive growth
TABLE 105 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 106 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 107 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 112 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 113 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 115 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 116 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 117 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 125 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government health policies to drive market
TABLE 129 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 130 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 135 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 136 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 139 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Availability of government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
TABLE 140 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 141 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 146 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 147 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 150 UK: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increasing government investments in genomics & proteomics research to drive market
TABLE 151 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 152 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 153 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 156 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 157 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 158 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 161 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population to support market growth
TABLE 162 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 163 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 164 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 168 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 169 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 172 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing focus on personalized medicine to propel market
TABLE 173 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 174 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 179 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 180 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 183 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 184 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 185 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 190 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 191 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 194 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 195 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 197 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Advancements in healthcare facilities to drive market
TABLE 207 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 208 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 209 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 214 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 215 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 218 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Research initiatives to support market growth
TABLE 219 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 220 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 221 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 222 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 226 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 227 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increased demand for early cancer diagnosis to drive market
TABLE 231 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 232 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 233 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 238 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 239 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 242 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 243 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 256 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 258 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 259 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 261 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 262 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 265 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Increasing incidence of cancer to drive market
TABLE 266 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 267 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 272 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 273 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 276 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Growing medical tourism to fuel demand for cancer diagnostics
TABLE 277 MEXICO: NUMBER OF CANCER CASES, BY CANCER TYPE, 2022
TABLE 278 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 279 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 284 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 285 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 288 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 289 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 295 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 296 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 299 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
TABLE 300 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 306 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 307 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 310 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11.7 GCC
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
TABLE 311 GCC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 312 GCC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 GCC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 314 GCC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 GCC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 GCC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 317 GCC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 318 GCC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 GCC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 GCC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 GCC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7.2 GCC: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER BIOMARKERS MARKET
TABLE 322 CANCER BIOMARKERS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2019–2023 (USD MILLION)
12.4 MARKET SHARE ANALYSIS
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 323 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT
12.5.5.1 Overall company footprint
FIGURE 39 CANCER BIOMARKERS MARKET: OVERALL COMPANY FOOTPRINT
12.5.5.2 Product footprint
TABLE 324 CANCER BIOMARKERS MARKET: PRODUCT FOOTPRINT
12.5.5.3 Profiling technology footprint
TABLE 325 CANCER BIOMARKERS MARKET: PROFILING TECHNOLOGY FOOTPRINT
12.5.5.4 Application footprint
TABLE 326 CANCER BIOMARKERS MARKET: APPLICATION FOOTPRINT
12.5.5.5 Regional footprint
TABLE 327 CANCER BIOMARKERS MARKET: REGIONAL FOOTPRINT
12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES (2023)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 40 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING
TABLE 328 CANCER BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 329 CANCER BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.7 VALUATION AND FINANCIAL METRICS OF CANCER BIOMARKER VENDORS
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 43 PRODUCT/BRAND COMPARATIVE ANALYSIS
12.8.1 F. HOFFMANN-LA ROCHE LTD.
12.8.2 AGILENT TECHNOLOGIES, INC.
12.8.3 QIAGEN
12.8.4 ABBOTT
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 330 CANCER BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
12.9.2 DEALS
TABLE 331 CANCER BIOMARKERS MARKET: DEALS, JANUARY 2021–MARCH 2024
13 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 332 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 333 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
TABLE 334 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 335 F. HOFFMANN-LA ROCHE LTD.: DEALS
13.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 336 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 337 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
TABLE 338 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 339 THERMO FISHER SCIENTIFIC INC.: DEALS
13.1.3 QIAGEN
TABLE 340 QIAGEN: COMPANY OVERVIEW
FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 341 QIAGEN: PRODUCTS & SERVICES OFFERED
TABLE 342 QIAGEN: PRODUCT LAUNCHES & APPROVALS
TABLE 343 QIAGEN: DEALS
13.1.4 BIO-RAD LABORATORIES, INC.
TABLE 344 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 345 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
13.1.5 ILLUMINA, INC.
TABLE 346 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 48 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 347 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
TABLE 348 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 349 ILLUMINA, INC.: DEALS
13.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS
13.1.7 ABBOTT LABORATORIES
TABLE 354 ABBOTT: COMPANY OVERVIEW
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
TABLE 355 ABBOTT: PRODUCTS & SERVICES OFFERED
13.1.8 BIOMЙRIEUX
TABLE 356 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 51 BIOMЙRIEUX: COMPANY SNAPSHOT (2023)
TABLE 357 BIOMЙRIEUX: PRODUCTS & SERVICES OFFERED
13.1.9 MERCK KGAA
TABLE 358 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 359 MERCK KGAA: PRODUCTS & SERVICES OFFERED
TABLE 360 MERCK KGAA: DEALS
TABLE 361 MERCK KGAA: OTHER DEVELOPMENTS
13.1.10 BECTON, DICKINSON AND COMPANY
TABLE 362 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 363 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MYRIAD GENETICS, INC.
13.2.2 SYSMEX CORPORATION
13.2.3 HOLOGIC, INC.
13.2.4 QUEST DIAGNOSTICS
13.2.5 CENTOGENE N.V.
13.2.6 BIOGENEX
TABLE 364 BIOGENEX: COMPANY OVERVIEW
13.2.7 SIEMENS HEALTHINEERS
13.2.8 EXACT SCIENCES
13.2.9 R&D SYSTEMS, INC.
13.2.10 BIOVISION INC.
13.2.11 OLINK
13.2.12 ASURAGEN, INC.
13.2.13 MESO SCALE DIAGNOSTICS, LLC
13.2.14 INVIVOSCRIBE, INC.
13.2.15 INOVIQ LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
